SK Bioscience Wins Patent Suit Against Pfizer, Eyes Global Pneumococcal Vaccine Market

[Yu Jin-hee, Edaily Reporter] SEOUL, South Korea-SK Bioscience has secured a decisive legal victory that may pave the way for its pneumococcal conjugate vaccine to reenter the global market.

The ruling marks a potential turning point for SK Bioscience, which had been barred from manufacturing or selling its domestic 13-valent pneumococcal conjugate vaccine, SKYNeumo, following an earlier loss in the patent dispute.

SK Bioscience is aiming to expand its global footprint, particularly as its next-generation pneumococcal vaccine pipeline advances.